Harpoon Therapeutics Is A Clinical Stage Immuno Oncology Company Dedicated To Developing T Cell Engagers For Cancer Treatmentthe Company Specializes In T Cell Engagement Therapiesutilizing Proprietary Platforms To Redirect The Immune System Against Cancer Cellsin January 2024Harpoon Was Acquired By Merck To Enhance Merckae S Oncology Pipeline The Companyae S Technology Includes The Tritacaplatformwhich Targets Tumor Antigens And Activates T Cells To Attack Solid Tumors And Hematologic Malignanciesother Platformssuch As Protritaca Cdeliver Inactive T Cell Engagers That Activate Within The Tumor Microenvironmentand Tritac Xrwhich Controls Drug Exposure To Mitigate Cytokine Release Syndromeharpoon S Pipeline Features Several Productsincluding Hpn536 For Ovarian Cancerhpn217 For Multiple Myelomahpn328 For Small Cell Lung Cancerand Hpn601 For Solid Tumors Harpoon Therapeutics Actively Conducts Clinical Trials And Collaborates With Research Institutions To Advance Its Therapiesfocusing On Solid Tumors And Hematologic Cancersthe Company Emphasizes Targeted Therapies To Minimize Off Target Effects And Addresses Various Clinical Needs Through Its Versatile Platforms
